Vyriad (Series B)
Funding Details
Awarder
Inbox
Date Award
December 24, 2025
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount
$25,000,000
Company Info
Traction
Ongoing corporate partnerships with Regeneron Pharmaceuticals and Novartis, and ongoing Phase 1-2 trials across multiple cancer indications.
Founders
Dr. Stephen Russell, Dr. Kah-Whye Peng
Market
Cancer and serious diseases
Location
Rochester, Minnesota, USA
Coinvestors
Regeneron Pharmaceuticals, Novartis
Company Description

Vyriad is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company uses engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells.

Links
Website
Back to HomeBack to Biotechnology DealsView Funding Announcement